Differences in reactivation of tuberculosis induced from anti-tnf treatments are based on bioavailability in granulomatous tissue

PLoS Computational Biology

Volumn 3, Issue 10, 2007, Pages 1909-1924

  Marino, Simeone ^a   Sud, Dhruv ^a,b   Plessner, Hillarie ^c   Lin, Philana Ling ^d   Chan, John ^e   Flynn, JoAnne L ^c   Kirschner, Denise E ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOLOGY; BIOCHEMISTRY; CONTROLLED DRUG DELIVERY;

ANIMAL STUDIES; ANTI-TUMORS; COMPUTATIONAL APPROACH; EXPERIMENTAL EVIDENCE; HOST DEFENSE; IMMUNE RESPONSE; INFLAMMATORY DISORDERS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS INFECTION; TUMOR NECROSIS FACTORS;

PATHOLOGY;

TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BIOAVAILABILITY; DRUG MECHANISM; GRANULOMATOUS INFLAMMATION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFECTION; INFECTION CONTROL; MATHEMATICAL MODEL; MYCOBACTERIUM TUBERCULOSIS; RECURRENT DISEASE; RISK; TUBERCULOSIS;

ANIMALIA; MYCOBACTERIUM TUBERCULOSIS;

EID: 35748953415     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.0030194     Document Type: Article

References (62)

1. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, et al. (2001) Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology. Infect Immun 69: 1847-1855.
2. Bean AG, Roach DR, Briscoe H, France MP, Korner H, et al. (1999) Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 162: 3504-3511.
3. Bekker LG, Moreira AL, Bergtold A, Freeman S, Ryffel B, et al. (2000) Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent. Infect Immun 68: 6954-6961.
4. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, et al. (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2: 561-572.
5. Denis M, Gregg EO, Ghandirian E (1990) Cytokine modulation of Mycobacterium tuberculosis growth in human macrophages. Int J Immunopharmacol 12: 721-727.
6. Algood HM, Lin PL, Yankura D, Jones A, Chan J, et al. (2004) TNF influences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during Mycobacterium tuberculosis infection. J Immunol 172: 6846-6857.
7. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, et al. (2002) TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168: 4620-4627.
8. Tracey KJ, Cerami A (1993) Tumor necrosis factor: An updated review of its biology. Crit Care Med 21: S415-S422.
9. Beutler B, Cerami A (1988) Tumor necrosis, cachexia, shock, and inflammation: A common mediator. Annu Rev Biochem 57: 505-518.
10. Bekker LG, Maartens G, Steyn L, Kaplan G (1998) Selective increase in plasma tumor necrosis factor-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. J Infect Dis 178: 580-584.
11. Ehlers S, Kutsch S, Ehlers EM, Benini J, Pfeffer K (2000) Lethal granuloma disintegration in mycobacteria-infected TNFRp55-/- mice is dependent on T cells and IL-12. J Immunol 165: 483-492.
12. Solomon KA, Covington MB, DeCicco CP, Newton RC (1997) The fate of pro-TNF-alpha following inhibition of metalloprotease-dependent processing to soluble TNF-alpha in human monocytes. J Immunol 159: 4524-4531.
13. Watts TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23: 23-68.
14. Smith CA, Farrah T, Goodwin RG (1994) The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 76: 959-962.
15. Ferran C, Dautry F, Merite S, Sheehan K, Schreiber R, et al. (1994) Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J Clin Invest 93: 2189-2196.
16. Harashima S, Horiuchi T, Hatta N, Morita C, Higuchi M, et al. (2001) Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol 166: 130-136.
17. Suzuki I, Fink PJ (1998) Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J Exp Med 187: 123-128.
18. Eissner G, Kirchner S, Lindner H, Kolch W, Janosch P, et al. (2000) Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 164: 6193-6198.
19. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, et al. (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121: 1145-1157.
20. Kirchner S, Holler E, Haffner S, Andreesen R, Eissner G (2004) Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 28: 67-74.
21. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, et al. (2004) Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 50: 353-363.
22. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, et al. (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 363: 675-681.
23. van Deventer SJ (2001) Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 121: 1242-1246.
24. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, et al. (2002) Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 359: 1541-1549.
25. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-1104.
26. Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2: 602-610.
27. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38: 1261-1265.
28. Wigginton JE, Kirschner D (2001) A model to predict cell-mediated immune regulatory mechanisms during human infection with Mycobacterium tuberculosis. J Immunol 166: 1951-1967.
29. Marino S, Pawar S, Fuller CL, Reinhart TA, Flynn JL, et al. (2004) Dendritic cell trafficking and antigen presentation in the human immune response to Mycobacterium tuberculosis. J Immunol 173: 494-506.
30. Kirschner D, Marino S (2005) Mycobacterium tuberculosis as viewed through a computer. Trends Microbiol 13: 206-211.
31. Sud D, Bigbee C, Flynn JL, Kirschner DE (2006) Contribution of CD8+ T cells to control of Mycobacterium tuberculosis infection. J Immunology 176: 4296-4314.
32. Capuano SV III, Croix DA, Pawar S, Zinovik A, Myers A, et al. (2003) Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun 71: 5831-5844.
33. Randhawa PS (1990) Lymphocyte subsets in granulomas of human tuberculosis: An in situ immunofluorescence study using monoclonal antibodies. Pathology 22: 153-155.
34. Tsao TC, Chen CH, Hong JH, Hsieh MJ, Tsao KC, et al. (2002) Shifts of T4/T8 T lymphocytes from BAL fluid and peripheral blood by clinical grade in patients with pulmonary tuberculosis. Chest 122: 1285-1291.
35. Lima MC, Pereira GM, Rumjanek FD, Gomes HM, Duppre N, et al. (2000) Immunological cytokine correlates of protective immunity and pathogenesis in leprosy. Scand J Immunol 51: 419-428.
36. Wong CF, Yew WW, Leung SK, Chan CY, Hui M, et al. (2003) Assay of pleural fluid interleukin-6, tumour necrosis factor-alpha and interferon-gamma in the diagnosis and outcome correlation of tuberculous effusion. Respir Med 97: 1289-1295.
37. Lin Y, Zhang M, Hofman FM, Gong J, Barnes PF (1996) Absence of a prominent Th2 cytokine response in human tuberculosis. Infect Immun 64: 1351-1356.
38. Saunders BM, Briscoe H, Britton WJ (2004) T cell-derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection. Clin Exp Immunol 137: 279-287.
39. Keane J, Remold HG, Kornfeld H (2000) Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J Immunol 164: 2016-2020.
40. Rojas M, Olivier M, Gros P, Barrera LF, Garcia LF (1999) TNF-alpha and IL-10 modulate the induction of apoptosis by virulent Mycobacterium tuberculosis in murine macrophages. J Immunol 162: 6122-6131.
41. Newton RC, Solomon KA, Covington MB, Decicco CP, Haley PJ, et al. (2001) Biology of TACE inhibition. Ann Rheum Dis 60 (Supplement 3): iii25-iii32.
42. Saunders BM, Tran S, Ruuls S, Sedgwick JD, Briscoe H, et al. (2005) Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 174: 4852-4859.
43. Olleros ML, Guler R, Vesin D, Parapanov R, Marchal G, et al. (2005) Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections. Am J Pathol 166: 1109-1120.
44. Nestorov I (2005) Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl 74: 13-18.
45. Tsao TC, Li L, Hsieh M, Liao S, Chang KS (1999) Soluble TNF-alpha receptor and IL-1 receptor antagonist elevation in BAL in active pulmonary TB. Eur Respir J 14: 490-495.
46. Plessner HL, Lin PL, Kohno T, Louie JS, Kirschner D, et al. (2007) Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 195: 1643-1650.
47. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, et al. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301: 418-426.
48. Neyrolles O, Hernandez-Pando R, Pietri-Rouxel F, Fornes P, Tailleux L, et al. (2006) Is adipose tissue a alace for Mycobacterium tuberculosis persistence? PLoS ONE 1: e43. doi:10.1371/journal.pone.0000043
49. Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10: 411-452.
50. Bemelmans MH, van Tits LJ, Buurman WA (1996) Tumor necrosis factor: Function, release and clearance. Crit Rev Immunol 16: 1-11.
51. van den Brande J, Hommes DW, Peppelenbosch MP (2005) Infliximab induced T lymphocyte apoptosis in Crohn's disease. J Rheumatol Suppl 74: 26-30.
52. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7: 251-259.
53. Oddo M, Renno T, Attinger A, Bakker T, MacDonald HR, et al. (1998) Fas ligand-induced apoptosis of infected human macrophages reduces the viability of intracellular Mycobacterium tuberculosis. J Immunol 160: 5448-5454.
54. Blower SM, Dowlatabadi H (1994) Sensitivity and uncertainty analysis of complex-models of disease transmission - An HIV model, as an example. Intl Stat Rev 62: 229-243.
55. Greenland S (2001) Sensitivity analysis, Monte Carlo risk analysis, and Bayesian uncertainty assessment. Risk Anal 21: 579-583.
56. Helton JC, Davis FJ (2002) Illustration of sampling-based methods for uncertainty and sensitivity analysis. Risk Anal 22: 591-622.
57. Sanchez MA, Blower SM (1997) Uncertainty and sensitivity analysis of the basic reproductive rate. Tuberculosis as an example. Am J Epidemiol 145: 1127-1137.
58. Kast RE (2005) Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: New insights into the biology of TNF-alpha giving new treatment opportunities - The role of bupropion. Leuk Res 29: 1459-1463.
59. Ameglio F, Casarini M, Capoluongo E, Mattia P, Puglisi G, et al. (2005) Post-treatment changes of six cytokines in active pulmonary tuberculosis: Differences between patients with stable or increased fibrosis. Int J Tuberc Lung Dis 9: 98-104.
60. Centocor (2003) Remicade (infliximab) prescribing information. Available: http://www.remicade.com. Accessed 12 September 2007.
61. Immunex Corporation (2003) Enbrel (etanercept) prescribing information. Available: http://www.enbrel.com. Accessed 12 September 2007.
62. Hehlgans T, Pfeffer K (2005) The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: Players, rules and the games. Immunology 115: 1-20.